F-star Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of F-star Therapeutics generated cash of -$27,267,000, which is less than the previous year. Cash used in financing activities reached the amount of $88,099,000 last year. Net change in cash is therefore $60,023,000.
Cash Flow
| 2016 | -15.84M | -6.47M | 28.66M |
|---|---|---|---|
| 2017 | -17.68M | -12.40M | 43.53M |
| 2018 | -25.24M | -25.10M | 41.17M |
| 2019 | -22.11M | 5.37M | 13.26M |
| 2020 | -16.22M | 14.04M | 15.85M |
| 2021 | -27.26M | -643K | 88.09M |
FSTX Cash Flow Statement (2016 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 18.52M | 4.90M | 8.19M | 24.13M | 10.68M | 4.34M |
Operating activities | ||||||
Net income | -31.28M | -25.61M | -23.01M | -22.85M | -27.67M | -17.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 642K | 1.14M | 844K | 288K | 158K | 118K |
Stock-based compensation expense | 6.89M | 3.48M | 2.66M | 2.77M | 1.91M | 1.43M |
| Deferred income tax benefit | 6.89M | 3.48M | 2.66M | 2.77M | 1.91M | 1.43M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.49M | -2.84M | 2.26M | 180K | 181K | -812K |
Cash generated by operating activities | -27.26M | -16.22M | -22.11M | -25.24M | -17.68M | -15.84M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | -15M | -58M | -34.39M | -14.97M |
Investments In Property Plant And Equipment | -658K | -730K | -127K | -1.97M | -323K | -213K |
Acquisitions Net | 0 | 0 | 5.49M | 0 | 0 | 0 |
Cash generated by investing activities | -643K | 14.04M | 5.37M | -25.10M | -12.40M | -6.47M |
Financing activities | ||||||
Common Stock Issued | 78.34M | 15M | 6K | 37.96M | 39.67M | 2.78M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 88.09M | 15.85M | 13.26M | 41.17M | 43.53M | 28.66M |
Net Change In Cash | 60.02M | 13.62M | -3.29M | -9.17M | 13.44M | 6.33M |
Cash at end of period | 78.54M | 18.52M | 4.90M | 14.95M | 24.13M | 10.68M |
| Data source | Data source | Data source | Data source | Data source | Data source |